Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jochen Schulze Grotthoff"'
Autor:
Johanna K. Freundt, Gerrit Frommeyer, Tilmann Spieker, Fabian Wötzel, Jochen Schulze Grotthoff, Jörg Stypmann, Georg Hempel, Michael Schäfers, Andreas H. Jacobs, Lars Eckardt, Philipp S. Lange
Publikováno v:
BMC Pharmacology and Toxicology, Vol 20, Iss 1, Pp 1-9 (2019)
Abstract Background The development of heart failure is accompanied by complex changes in cardiac electrophysiology and functional properties of cardiomyocytes and fibroblasts. Histone deacetylase (HDAC) inhibitors hold great promise for the pharmace
Externí odkaz:
https://doaj.org/article/7efda64f0274422f87b8bbf3dc46c0ac
Autor:
Simon Kochhäuser, Lars Eckardt, Gerrit Frommeyer, Jochen Schulze Grotthoff, Jörg Stypmann, Günter Breithardt, Peter Milberg, Michael Fehr, Dirk G. Dechering
Publikováno v:
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 17(8)
Aims Interaction between dronedarone and digitalis has been discussed as a possible cause for increased mortality in the presence of dronedarone observed in the PALLAS trial. The aim of this study was to assess possible proarrhythmic effects of drone
Autor:
Lars Eckardt, Christian Pott, Gerrit Frommeyer, Fabian Grundmann, Sven Kaese, Peter Milberg, Catharina Clauss, Jochen Schulze Grotthoff, Shahram Ramtin, Marco Schmidt
Publikováno v:
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 16(8)
Aim The most recent European Society of Cardiology (ESC) update on atrial fibrillation has introduced vernakalant (VER) for pharmacological cardioversion of atrial fibrillation. The aim of the present study was to investigate the safety profile of VE
Autor:
Christina Fischer, Dirk G. Dechering, Lars Eckardt, Florian Reinke, Jochen Schulze Grotthoff, Peter Milberg, Simon Kochhäuser, Gerrit Frommeyer, Harilaos Bogossian, Michael Fehr
Publikováno v:
Journal of cardiac failure. 20(10)
Background The present ESC guidelines on atrial fibrillation have introduced vernakalant (VER) for pharmacologic cardioversion of atrial fibrillation. The aim of the present study was to investigate possible proarrhythmic effects of vernakalant in an